June - 2018

MECFA Blog

Award granted to Neem Biotech to develop antimicrobial intervention for chronic lung infections

Neem Biotech, a Wales based R&D pharmaceutical biotech working in the field of novel antimicrobial drug development, is pleased to...

Understanding How Bacteria ‘Talk’ Could Hold Key for New CF Treatments, Study Suggests

New research provides insights into how bacteria “talk” to each other in lung infections, which could provide strategies to block these...

The 2019 European Cystic Fibrosis Conference to be held in Liverpool

ACC Liverpool will be the venue for the European Cystic Fibrosis Conference, to be held in the city for the first time. ACC Liverpool...

#ECFS2018 – Multiple Sclerosis Therapy Boosts Antibiotic’s Ability to Kill Resistant P. aeruginosa S

Combining the approved multiple sclerosis treatment glatiramer acetate with the antibiotic tobramycin improved its ability to kill...

#ECFS2018 – 3 Scientists Win 2018 ‘Young Investigators Awards’ for Innovative CF Research

The European Cystic Fibrosis Society presented three scientists — one Portuguese, one Mexican, and one German — with the organization’s...

#ECFS2018 – AB-PA01, with Antibiotics, Shows Promise in Treating Drug-resistant Lung Infections in C

AmpliPhi Biosciences’ investigative therapy AB-PA01, in combination with antibiotics, shows significant potential to treat multi-drug...

PTI-808

PTI-808 is an experimental therapy being developed by Proteostasis Therapeutics to treat the most common type of cystic fibrosis (CF)...

#ECFS2018 — Hard-to-Treat Infections May Not Impact Survival of CF Patients After Lung Transplant, S

One-year survival after a lung transplant of cystic fibrosis (CF) patients chronically infected with antibiotic-resistant bacteria is...

Scientists work to dissolve the NETs that worsen TBI damage

Immune cells that are first responders to a traumatic brain injury appear to also contribute to the secondary damage that can occur even...

Spyryx SPX-101 Phase 2 HOPE-1 Trial Shows Improvement in Lung Function in Patients with Cystic Fibro

DURHAM, N.C., June 6, 2018 /PRNewswire/ -- Today Spyryx shared positive data for the first cohort of the SPX-101 Phase 2 clinical trial...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p